GET DAILY SIGNALSMyomo (MYO): Assessing the Path to the $4.75 Analyst Target and +290% Upside
Key Takeaways
- The central target of $4.75 represents the arithmetic mean of five verified analyst price targets for Myomo, Inc. (MYO), a wearable medical robotics company.
- Individual targets range from $1.70 (Craig-Hallum) to $11.00 (Ascendiant Capital), highlighting notable differences in views on the company’s outlook.
- At a recent price near $1.21, reaching $4.75 would imply roughly a +290% advance — a substantial move under any measure.
- All five covering analysts rate MYO a Buy or Strong Buy, yet their price targets differ by nearly sevenfold.
- Key supporting elements include expanding revenue and a projected route to $100 million in revenue by 2028; primary risks involve ongoing losses and margin pressures.
- Additional details on Major News, Today's Price Move, Forecast, and Earnings for Myomo are available on Tickeron’s dedicated pages.
Analyst Price Targets and Consensus View
Myomo, Inc. develops and produces myoelectric orthotics, most notably the MyoPro powered upper-limb brace, for individuals with neuromuscular disorders. The stock trades on the NYSE American exchange. Five analysts currently cover MYO, and all five maintain Buy or Strong Buy ratings. Their price targets from recent reports are: Ascendiant Capital at $11.00, H.C. Wainwright at $5.00, Maxim Group at $3.00, Alliance Global Partners at $3.00, and Craig-Hallum at $1.70. The arithmetic mean of these five targets comes to approximately $4.74, which rounds to a central target of $4.75.
The range remains exceptionally wide — from $1.70 to $11.00 — so the average is not a tight consensus. Craig-Hallum’s Chase Knickerbocker has adjusted his target downward over time as cost recovery has lagged expectations, while Ascendiant’s Edward Woo holds a higher target based on a longer-term net-present-value analysis. This spread points to real uncertainty around how quickly Myomo can turn revenue growth into profits. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
MYO closed near $1.21 in early November 2026, resulting in a market capitalization of roughly $48 million. Trailing twelve-month revenue stood at about $43.3 million, with a net loss near $14.5 million and negative EPS of about -$0.35. The 52-week range spans roughly $0.61 to $1.89.
Reaching $4.75 would require an advance of approximately +290% from current levels — a very large move that would place the market value well above recent trading history. For context, the stock’s entire 52-week high sits near $1.89, so the central target lies more than two-and-a-half times above that recent peak.
What Could Support a Move Toward the Target
The bullish case centers on durable demand growth. Myomo reported quarterly revenue of $11.7 million in the quarter ended June 30, 2026, up from $9.65 million a year earlier, and management has outlined a path toward roughly $100 million in revenue by 2028. Expanding reimbursement access, including Medicare coverage pathways, and growing adoption of the MyoPro device remain central to that trajectory.
Analysts point to a large underserved patient population, rising procedural awareness, and improving gross margins as foundations for a potential re-rating. Because the stock trades at roughly 1.3 times trailing sales, even modest progress toward sustained profitability could support a higher valuation multiple.
What Could Prevent the Target From Being Reached
The main obstacle remains execution and cash economics. Myomo continues to report negative EPS and negative levered free cash flow, and its path to break-even hinges on both revenue scale and disciplined cost control. Craig-Hallum’s lower target reflects precisely this concern over slower-than-anticipated cost improvements.
Additional risks include reliance on Medicare and private-insurance reimbursement decisions, a concentrated product line, competition in the medical-device space, and the possibility of dilutive capital raises given the company’s modest cash position. A failure to sustain revenue growth or expand margins could keep the stock well below the average analyst price target.
Technical Levels and Market Structure
MYO has spent much of the past year trading between roughly $0.60 and $1.90, with the $1.85–$1.90 zone serving as a notable resistance level. A decisive move above that area would mark a breakout to multi-year highs. On the downside, the $1.10–$1.20 region has acted as recurring support, while the $1.00 psychological level and the $0.60 area represent deeper support zones. The wide gap between the current price and the $4.75 target suggests the technical path would require sustained, multi-stage rallies rather than a single catalyst-driven move.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months. Investors should watch the next quarterly earnings report, scheduled for November 9, 2026, along with subsequent revenue guidance, gross-margin trends, and cash-burn commentary. Reimbursement developments, particularly any changes to Medicare coverage policy, and analyst target revisions are also key signposts.
Leveraging AI Tools for Deeper Insights
In my own research process, I frequently turn to Tickeron’s AI Daily Buy/Sell Signals to monitor stocks like MYO. These signals use artificial intelligence to track thousands of securities and generate Buy, Sell, or Hold indications based on technical behavior and market conditions. For a small-cap name trading on shifting sentiment, this approach helps identify opportunities and track trends more systematically alongside traditional analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
MYO in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 13, 2026
MYO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 37 cases where MYO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MYO's RSI Indicator exited the oversold zone, 30 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 60 cases where MYO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MYO as a result. In 61 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for MYO just turned positive on November 03, 2026. Looking at past instances where MYO's MACD turned positive, the stock continued to rise in 27 of 40 cases over the following month. The odds of a continued upward trend are 68%.
Following a +8.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where MYO advanced for three days, in 197 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
MYO moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MYO crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MYO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MYO entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.221) is normal, around the industry mean (4.142). P/E Ratio (-3.559) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.262) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. MYO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MYO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of neuro-robotic technology
Industry MedicalNursingServices
Advertisement